Abstract
The combination of venetoclax and hypomethylating agent (HMA/venetoclax) has emerged as a treatment option for patients with de novo acute myeloid leukemia (AML) who are unfit to receive intensive chemotherapy. In this single-center retrospective study, we evaluated clinical outcomes following treatment with HMA/venetoclax in 35 patients with advanced myeloproliferative neoplasms, myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes or AML with extramedullary disease. The composite complete remission (CR) rate (including confirmed/presumed complete cytogenetic response, acute leukemia response-complete, CR and CR with incomplete hematologic recovery) was 42.9% with median overall survival (OS) of 9.7 months. Complex karyotype was associated with inferior median OS (3.7 versus 12.2 months; p = 0.0002) and composite CR rate (22% versus 50.0%; p = 0.2444). Although SRSF2 mutations were associated with higher composite CR rate (80.0% versus 28.0%; p = 0.0082), this was not associated with longer median OS (10.9 versus 8.0 months; p = 0.2269). Future studies should include these patient subgroups.
Original language | English (US) |
---|---|
Pages (from-to) | 846-855 |
Number of pages | 10 |
Journal | Leukemia and Lymphoma |
Volume | 64 |
Issue number | 4 |
DOIs | |
State | Published - 2023 |
Keywords
- Myeloproliferative neoplasm
- acute myeloid leukemia
- azacitidine
- decitabine
- extramedullary disease
- hypomethylating agents
- myelodysplastic/myeloproliferative neoplasm
- venetoclax
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research